Literature DB >> 22371224

Diagnostic value of neutrophil gelatinase-associated lipocalin (NGAL) immunoexpression in follicular-patterned lesions of the thyroid gland.

Valeria Barresi1, Enrica Vitarelli, Luca Reggiani Bonetti, Giovanni Tuccari, Gaetano Barresi.   

Abstract

Neutrophil gelatinase-associated lipocalin (NGAL) is a protein which participates in iron trafficking and which is involved in cancerogenesis and cancer progression. Since its over-expression has been documented in thyroid malignancies in comparison to thyroid normal gland, in the present study, we aimed to determine whether the evaluation of NGAL immunoexpression may be of help in the differential diagnosis of follicular-patterned thyroid lesions. Our additional aim was to test the possible interference of endogenous biotin on the immunohistochemical findings. Thus, all the immunohistochemical procedures, carried out with labeled streptavidin biotin method, were doubly performed, with or without the preliminary inhibition of endogenous biotin. No NGAL staining was found in the normal thyroid gland nor in the nodular colloid goiters or in Hashimoto's thyroiditis. NGAL expression appeared to be significantly more frequent in the malignant tumors in comparison to benign ones (P < 0.000001). Even more, NGAL expression appeared to be specific (specificity 93%) for carcinoma and represented a sensitive method (sensitivity 84%), with high negative (88%) and positive (94%) predictive values, as well as high diagnostic accuracy (88%), in the identification of follicular-patterned thyroid malignant tumors. The specificity, positive predictive value and diagnostic accuracy lowered when biotin was not preliminary inhibited, due to the presence of false positives among benign Hürthle cell tumors. In conclusion, the immunohistochemical detection of NGAL may be helpful in the differential diagnosis between malignant and benign follicular-patterned lesions of the thyroid. The use of biotin free system or the preliminary biotin inhibition is warranted for the detection of NGAL in thyroid samples, especially when dealing with Hürthle cell tumors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22371224     DOI: 10.1007/s00428-012-1208-0

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  33 in total

1.  Neutrophil gelatinase-associated lipocalin immunoexpression in renal tumors: correlation with histotype and histological grade.

Authors:  Valeria Barresi; Antonio Ieni; Davide Bolignano; Carlo Magno; Michele Buemi; Gaetano Barresi
Journal:  Oncol Rep       Date:  2010-08       Impact factor: 3.906

2.  Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin.

Authors:  D H Goetz; S T Willie; R S Armen; T Bratt; N Borregaard; R K Strong
Journal:  Biochemistry       Date:  2000-02-29       Impact factor: 3.162

Review 3.  Lipocalins and cancer.

Authors:  T Bratt
Journal:  Biochim Biophys Acta       Date:  2000-10-18

4.  Retrieved endogenous biotin: a novel marker and a potential pitfall in diagnostic immunohistochemistry.

Authors:  G Bussolati; P Gugliotta; M Volante; M Pace; M Papotti
Journal:  Histopathology       Date:  1997-11       Impact factor: 5.087

5.  Neutrophil gelatinase-associated lipocalin (NGAL) immunohistochemical expression in follicular cell-derived thyroid tumors: a novel diagnostic tool?

Authors:  V Barresi; A Leni; G Tuccari; G Barresi
Journal:  Histol Histopathol       Date:  2012-03       Impact factor: 2.303

6.  An iron delivery pathway mediated by a lipocalin.

Authors:  Jun Yang; David Goetz; Jau Yi Li; Wenge Wang; Kiyoshi Mori; Daria Setlik; Tonggong Du; Hediye Erdjument-Bromage; Paul Tempst; Roland Strong; Jonathan Barasch
Journal:  Mol Cell       Date:  2002-11       Impact factor: 17.970

7.  Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer.

Authors:  Maret Bauer; Jens C Eickhoff; Michael N Gould; Christoph Mundhenke; Nicolai Maass; Andreas Friedl
Journal:  Breast Cancer Res Treat       Date:  2007-06-07       Impact factor: 4.872

8.  Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis.

Authors:  J E Barroeta; Z W Baloch; P Lal; T L Pasha; P J Zhang; V A LiVolsi
Journal:  Endocr Pathol       Date:  2006       Impact factor: 4.056

9.  Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors.

Authors:  Sunyoung Lee; Shahla M Jilani; Ganka V Nikolova; Darren Carpizo; M Luisa Iruela-Arispe
Journal:  J Cell Biol       Date:  2005-05-23       Impact factor: 10.539

10.  Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid.

Authors:  Dina El Demellawy; Ahmed Nasr; Salem Alowami
Journal:  Diagn Pathol       Date:  2008-02-06       Impact factor: 2.644

View more
  7 in total

1.  Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto's thyroiditis.

Authors:  Heng Ma; Jin Yan; Chao Zhang; Shenghui Qin; Lingzhi Qin; Liwei Liu; Xi Wang; Naping Li
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

Review 2.  Implication and role of neutrophil gelatinase-associated lipocalin in cancer: lipocalin-2 as a potential novel emerging comprehensive therapeutic target for a variety of cancer types.

Authors:  Sina Rahimi; Amaneh Mohammadi Roushandeh; Ebrahim Ahmadzadeh; Ali Jahanian-Najafabadi; Mehryar Habibi Roudkenar
Journal:  Mol Biol Rep       Date:  2020-01-22       Impact factor: 2.316

3.  Up-regulated lipocalin-2 in pediatric thyroid cancer correlated with poor clinical characteristics.

Authors:  Jun Tai; Shengcai Wang; Jie Zhang; Wentong Ge; Yuanhu Liu; Xiaodan Li; Yuwei Liu; Zhijuan Deng; Lejian He; Guoliang Wang; Xin Ni
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-09-04       Impact factor: 2.503

Review 4.  Lipocalin 2 (LCN2) Expression in Hepatic Malfunction and Therapy.

Authors:  Anastasia Asimakopoulou; Sabine Weiskirchen; Ralf Weiskirchen
Journal:  Front Physiol       Date:  2016-09-27       Impact factor: 4.566

5.  PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.

Authors:  Jianfeng Wang; Chen Wang; Pan Xu; Xiao Li; Yongning Lu; Di Jin; Xiaomao Yin; Hao Jiang; Jing Huang; Huan Xiong; Fei Ye; Jia Jin; Yu Chen; Yiqian Xie; Zhifeng Chen; Hong Ding; Hao Zhang; Rongfeng Liu; Hualiang Jiang; Kaixian Chen; Zhiyi Yao; Cheng Luo; Yiran Huang; Yuanyuan Zhang; Jin Zhang
Journal:  Theranostics       Date:  2021-03-12       Impact factor: 11.556

6.  Bioinformatic analysis of the LCN2-SLC22A17-MMP9 network in cancer: The role of DNA methylation in the modulation of tumor microenvironment.

Authors:  Saverio Candido; Barbara Tomasello; Alessandro Lavoro; Luca Falzone; Giuseppe Gattuso; Angela Russo; Sabrina Paratore; James A McCubrey; Massimo Libra
Journal:  Front Cell Dev Biol       Date:  2022-09-21

7.  Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer.

Authors:  Saverio Candido; Roberta Maestro; Jerry Polesel; Alessia Catania; Francesca Maira; Santo S Signorelli; James A McCubrey; Massimo Libra
Journal:  Oncotarget       Date:  2014-03-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.